Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02674529 · ClinicalTrials.gov registry record · Phase 2

Study of Neural Responses Induced by Antidepressant Effects

A Phase 2 study, sponsored by Marta Peciña, MD PhD.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target

NCT02674529: Completed Phase 2 study, sponsored by Marta Peciña, MD PhD.

NCT02674529 is a Phase 2 study that has completed, run by Marta Peciña, MD PhD. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02674529, a Phase 2 study, has completed, sponsored by Marta Peciña, MD PhD.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

The proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.

Primary Outcome

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. It was designed in 1979 by British and Swedish researchers as an adjunct to the Hamilton Rating Scale for Depression (HAMD) which would be more sensitive to the changes brought on by antidepressants and other forms of treatment than the Hamilton Scale was.\[2\] There is, however, a high degree of stati

Interventions

  • DRUG Placebo
  • DRUG Escitalopram
  • BEHAVIORAL Real-time Neurofeedback fMRI task pre- and post-RCT

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2016-09
Est. Completion 2021-05
Phase Phase 2
Marta Peciña, MD PhD

4 total trials

What the finished NCT02674529 record still lists

NCT02674529 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02674529 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02674529 about?

NCT02674529 is a clinical study titled "Study of Neural Responses Induced by Antidepressant Effects". The proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.

What is the current status of trial NCT02674529?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2016-09. Estimated completion is 2021-05.

What interventions are being tested in trial NCT02674529?

The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), Real-time Neurofeedback fMRI task pre- and post-RCT (BEHAVIORAL).

Who is sponsoring clinical trial NCT02674529?

This trial is sponsored by Marta Peciña, MD PhD, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02674529's enrollment target sits among peer trials

60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02674529, the US trial registry maintained by the National Library of Medicine. NCT02674529 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.